Want to see SLXN full AI Analyst Report?
SLXN Stock Chart & Stats
$0.36
-$0.11(-4.62%)
At close: 4:00 PM EDT
$0.36
-$0.11(-4.62%)
Day’s Range― - ―
52-Week Range$0.35 - $80.00
Previous CloseN/A
Volume10.76K
Average Volume (3M)445.42K
Market Cap
$2.09M
Enterprise Value$0.90
Total Cash (Recent Filing)$2.23M
Total Debt (Recent Filing)$1.41M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Nov 18, 2026EPS Estimate
-9.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-56.54
Shares Outstanding5,755,872
10 Day Avg. Volume265,776
30 Day Avg. Volume445,424
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.98
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)-53.1
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressInitiating a Phase 2/3 study moves SIL204 beyond early development and creates a defined path toward clinical validation. Progress across Israeli and German sites could generate important efficacy and safety evidence over the next several months.
Differentiated RNAi Oncology PlatformSIL204 addresses KRAS-driven cancers through upstream gene silencing and dual delivery intended to reach primary and metastatic disease. If clinical data support the preclinical rationale, this could differentiate the platform in a high-need oncology market.
Recent Capital RaiseThe financing replenishes the capital base and provides resources to advance the SIL204 trial and fund corporate needs. Although limited relative to development requirements, it reduces immediate funding pressure and supports continued clinical execution.
Bears Say
Pre-Revenue Operating ModelSilexion has no marketed product revenue and remains dependent on successful clinical development, licensing or future financing. Continued losses without operating sales limit financial resilience and leave the business exposed to development and regulatory failure.
Cash Burn And Balance-Sheet StrainPersistent cash consumption and near-depleted equity materially restrict financial flexibility. Debt-to-equity was approximately 32x, indicating reliance on repeated external funding and raising the risk that capital needs could interrupt or dilute clinical progress.
Nasdaq Listing Compliance RiskAn unsuccessful appeal could remove the shares and warrants from Nasdaq, reducing liquidity, visibility and access to institutional capital. The issue also highlights that the recent financing must translate into sustained compliance rather than a temporary balance-sheet improvement.
Silexion Therapeutics News
SLXN FAQ
What was Silexion Therapeutics’s price range in the past 12 months?
Silexion Therapeutics lowest stock price was $0.35 and its highest was $80.00 in the past 12 months.
What is Silexion Therapeutics’s market cap?
Silexion Therapeutics’s market cap is $2.09M.
When is Silexion Therapeutics’s upcoming earnings report date?
Silexion Therapeutics’s upcoming earnings report date is Nov 18, 2026 which is in 77 days.
How were Silexion Therapeutics’s earnings last quarter?
Silexion Therapeutics released its earnings results on Aug 14, 2026. The company reported -$5.17 earnings per share for the quarter, beating the consensus estimate of -$21.2 by $16.03.
Is Silexion Therapeutics overvalued?
According to Wall Street analysts Silexion Therapeutics’s price is currently Overvalued.
Does Silexion Therapeutics pay dividends?
Silexion Therapeutics does not currently pay dividends.
What is Silexion Therapeutics’s EPS estimate?
Silexion Therapeutics’s EPS estimate is -9.1.
How many shares outstanding does Silexion Therapeutics have?
Silexion Therapeutics has 5,755,872 shares outstanding.
What happened to Silexion Therapeutics’s price movement after its last earnings report?
Silexion Therapeutics reported an EPS of -$5.17 in its last earnings report, beating expectations of -$21.2. Following the earnings report the stock price went down -8.696%.
Which hedge fund is a major shareholder of Silexion Therapeutics?
Currently, no hedge funds are holding shares in SLXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Silexion Therapeutics
Silexion Therapeutics LTD is a biopharmaceutical company specializing in the discovery and advancement of RNA interference (RNAi)-based cancer therapies and their associated delivery systems, with a focus on treating aggressive solid tumors. The company's strategy for addressing these tumors relies on its proprietary LODER delivery platform. Its product pipeline features several key candidates: SiG12D-LODER, which has progressed through both preclinical studies and an open-label Phase I clinical trial for pancreatic cancer; Prostate-LODER, currently undergoing preclinical evaluation for prostate cancer; and GBM-LODER, also in preclinical development, targeting Glioblastoma Multiforme, a highly malignant primary brain tumor. Founded in 2008, Silexion Therapeutics is headquartered in Jerusalem, Israel.
SLXN Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
10.00% Insiders
<0.01% Other Institutional Investors
89.99% Public Companies and
Individual Investors